John Field

List of Publications by Year in descending order

382 papers	24,741 citations	8181 76 h-index	10158 140 g-index
393 all docs	393 docs citations	393 times ranked	27097 citing authors

#	Article	IF	Citations
1	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	27.8	1,634
2	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
3	A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 2008, 452, 633-637.	27.8	1,169
4	Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15785-15790.	7.1	757
5	The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 33-38.	0.8	554
6	Lung cancer susceptibility locus at 5p15.33. Nature Genetics, 2008, 40, 1404-1406.	21.4	514
7	A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma. American Journal of Human Genetics, 2009, 85, 679-691.	6.2	489
8	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature Genetics, 2017, 49, 1126-1132.	21.4	472
9	European position statement on lung cancer screening. Lancet Oncology, The, 2017, 18, e754-e766.	10.7	428
10	The LLP risk model: an individual risk prediction model for lung cancer. British Journal of Cancer, 2008, 98, 270-276.	6.4	406
11	Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer, 1995, 75, 1343-1353.	4.1	313
12	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. Journal of Thoracic Oncology, 2019, 14, 343-357.	1.1	306
13	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	2.5	278
14	UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax, 2016, 71, 161-170.	5.6	263
15	Hypomethylation of retrotransposable elements correlates with genomic instability in nonâ€small cell lung cancer. International Journal of Cancer, 2009, 124, 81-87.	5.1	259
16	Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. British Journal of Cancer, 1991, 64, 573-577.	6.4	250
17	A Prognostic DNA Methylation Signature for Stage I Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4140-4147.	1.6	250
18	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature Communications, 2014, 5, 3518.	12.8	239

#	Article	IF	Citations
19	Lung cancer LDCT screening and mortality reduction â€" evidence, pitfalls and future perspectives. Nature Reviews Clinical Oncology, 2021, 18, 135-151.	27.6	234
20	Monosomy 3 in Uveal Melanoma: Correlation with Clinical and Histologic Predictors of Survival. , 2003, 44, 1008.		223
21	SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma. Journal of Thoracic Oncology, 2011, 6, 1632-1638.	1.1	220
22	Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncology, 2000, 36, 256-263.	1.5	210
23	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technology Assessment, 2016, 20, 1-146.	2.8	204
24	Promoter methylation of P16, RARÎ², E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. British Journal of Cancer, 2006, 94, 561-568.	6.4	199
25	Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Human Molecular Genetics, 2012, 21, 4980-4995.	2.9	196
26	UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax, 2011, 66, 308-313.	5.6	190
27	SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer, 2010, 10, 600.	2.6	169
28	Predictive Accuracy of the Liverpool Lung Project Risk Model for Stratifying Patients for Computed Tomography Screening for Lung Cancer. Annals of Internal Medicine, 2012, 157, 242.	3.9	162
29	RHBDF2 Mutations Are Associated with Tylosis, a Familial Esophageal Cancer Syndrome. American Journal of Human Genetics, 2012, 90, 340-346.	6.2	162
30	Previous Lung Diseases and Lung Cancer Risk: A Pooled Analysis From the International Lung Cancer Consortium. American Journal of Epidemiology, 2012, 176, 573-585.	3.4	160
31	DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Research, 2010, 12, R77.	5.0	159
32	A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium. PLoS Genetics, 2011, 7, e1001333.	3.5	158
33	Expression profiling of primary non-small cell lung cancer for target identification. Oncogene, 2002, 21, 7749-7763.	5.9	145
34	Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncology, 2000, 36, 311-327.	1.5	143
35	Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium. European Journal of Cancer, 2012, 48, 1957-1968.	2.8	143
36	Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. European Journal of Cancer Part B, Oral Oncology, 1992, 28, 67-76.	0.9	141

#	Article	IF	Citations
37	The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). Anticancer Research, 1990, 10, 1-22.	1.1	137
38	Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open, 2015, 5, e008254.	1.9	136
39	Integrative and comparative genomic analyses identify clinicallyÂrelevant pulmonary carcinoidÂgroups and unveil the supra-carcinoids. Nature Communications, 2019, 10, 3407.	12.8	132
40	Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. International Journal of Epidemiology, 2010, 39, 563-577.	1.9	125
41	Prospects for population screening and diagnosis of lung cancer. Lancet, The, 2013, 382, 732-741.	13.7	121
42	DNA Methylation Biomarkers Offer Improved Diagnostic Efficiency in Lung Cancer. Cancer Research, 2012, 72, 5692-5701.	0.9	120
43	The clinical determinants of malignant transformation in oral epithelial dysplasia. Oral Oncology, 2012, 48, 969-976.	1.5	117
44	Epigenetic biomarkers in lung cancer. Cancer Letters, 2014, 342, 200-212.	7.2	114
45	Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. British Journal of Cancer, 1995, 72, 1180-1188.	6.4	112
46	The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening. Cancer Prevention Research, 2014, 7, 362-371.	1.5	112
47	The Role of the p53 Tumor Suppressor Gene in Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology, 1993, 119, 1118-1122.	1.2	111
48	Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinomas of the head and neck. , 1996, 66, 464-469.		110
49	Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 25-32.	0.8	109
50	Lung cancer and socioeconomic status in a pooled analysis of case-control studies. PLoS ONE, 2018, 13, e0192999.	2.5	107
51	Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer, 2019, 134, 79-84.	2.0	105
52	Lung Cancer Risk Prediction to Select Smokers for Screening CTâ€"a Model Based on the Italian COSMOS Trial. Cancer Prevention Research, 2011, 4, 1778-1789.	1.5	104
53	Exposure to secondhand tobacco smoke and lung cancer by histological type: A pooled analysis of the International Lung Cancer Consortium (ILCCO). International Journal of Cancer, 2014, 135, 1918-1930.	5.1	100
54	Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Thorax, 2017, 72, 912-918.	5.6	99

#	Article	IF	Citations
55	Alterations of the p16-pRb Pathway and the Chromosome Locus 9p21â€“22 in Non-Small-Cell Lung Carcinomas. American Journal of Pathology, 1998, 153, 1749-1765.	3.8	97
56	Is Previous Respiratory Disease a Risk Factor for Lung Cancer?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 549-559.	5.6	97
57	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clinical Chemistry, 2017, 63, 1288-1296.	3.2	97
58	THE LEVEL OF CERVICAL LYMPH NODE METASTASES: THEIR PROGNOSTIC RELEVANCE AND RELATIONSHIP WITH HEAD AND NECK SQUAMOUS CARCINOMA PRIMARY SITES. Clinical Otolaryngology, 1994, 19, 63-69.	1.2	96
59	UHRF1â€mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer, 2011, 117, 1027-1037.	4.1	96
60	Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene, 1989, 4, 1463-8.	5.9	96
61	Lung cancer risk prediction: A tool for early detection. International Journal of Cancer, 2007, 120, 1-6.	5.1	95
62	Occupational Exposure to Crystalline Silica and Risk of Lung Cancer. Epidemiology, 2007, 18, 36-43.	2.7	94
63	European randomized lung cancer screening trials: Post NLST. Journal of Surgical Oncology, 2013, 108, 280-286.	1.7	94
64	Cytoglobin, the Newest Member of the Globin Family, Functions as a Tumor Suppressor Gene. Cancer Research, 2008, 68, 7448-7456.	0.9	93
65	International Lung Cancer Consortium: Pooled Analysis of Sequence Variants in DNA Repair and Cell Cycle Pathways. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3081-3089.	2.5	93
66	Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal, 2012, 40, 177-184.	6.7	92
67	Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. British Journal of Cancer, 1995, 72, 123-128.	6.4	91
68	Sex differences in sexual needs and desires. Archives of Sexual Behavior, 1984, 13, 233-245.	1.9	87
69	p16 Promoter Methylation Is a Potential Predictor of Malignant Transformation in Oral Epithelial Dysplasia. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2174-2179.	2.5	87
70	DNA Methylation of the Homeobox Genes PITX2 and SHOX2 Predicts Outcome in Nonâ€“small-cell Lung Cancer Patients. Diagnostic Molecular Pathology, 2012, 21, 93-104.	2.1	87
71	Microsatellite instability in squamous cell carcinoma of the head and neck. British Journal of Cancer, 1995, 71, 1065-1069.	6.4	84
72	Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Systems Biology, 2013, 7, S1.	3.0	83

#	Article	IF	Citations
73	Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Regional Health - Europe, The, 2021, 10, 100179.	5.6	82
74	Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Research, 2006, 34, e78-e78.	14.5	81
75	Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. Journal of Thoracic Oncology, 2019, 14, 1594-1607.	1.1	81
76	Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool familyâ€"A review of six generations. European Journal of Cancer Part B, Oral Oncology, 1994, 30, 102-112.	0.9	80
77	Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. British Journal of Cancer, 1998, 78, 950-957.	6.4	80
78	Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PLoS ONE, 2017, 12, e0177875.	2.5	79
79	Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Research, 1985, 5, 221-4.	1.1	79
80	Synchronous oral carcinomas: independent or common clonal origin?. Cancer Research, 1998, 58, 2003-6.	0.9	79
81	Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies. PLoS Genetics, 2012, 8, e1003032.	3.5	78
82	K-ras Point Mutation Detection in Lung Cancer: Comparison of Two Approaches to Somatic Mutation Detection Using ARMS Allele-specific Amplification. Clinical Chemistry, 2000, 46, 1929-1938.	3.2	77
83	Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. Journal of Pathology, 2003, 200, 610-619.	4.5	77
84	Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. Lancet, The, 1992, 339, 502-503.	13.7	74
85	Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. Thorax, 2016, 71, 996-1005.	5.6	74
86	Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization. International Journal of Cancer, 2021, 148, 1077-1086.	5.1	73
87	Tylosis oesophageal cancer mapped. Nature Genetics, 1994, 8, 319-321.	21.4	71
88	Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. International Journal of Oncology, 2012, 40, 825-32.	3.3	71
89	Exposureâ€"Response Analyses of Asbestos and Lung Cancer Subtypes in a Pooled Analysis of Caseâ€"Control Studies. Epidemiology, 2017, 28, 288-299.	2.7	71
90	Downregulation of the KIP family members p27^{KIP1} and p57^{KIP2} by SKP2 and the role of methylation in p57^{KIP2} inactivation in nonsmall cell lung cancer. International Journal of Cancer, 2006, 119, 2546-2556.	5.1	70

#	Article	IF	Citations
91	Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. Carcinogenesis, 2012, 33, 587-597.	2.8	69
92	Cytoglobin: biochemical, functional and clinical perspective of the newest member of the globin family. Cellular and Molecular Life Sciences, 2011, 68, 3869-3883.	5.4	68
93	Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. British Journal of Cancer, 2020, 122, 1050-1058.	6.4	68
94	Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer. British Journal of Cancer, 2009, 101, 139-144.	6.4	65
95	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Translational Lung Cancer Research, 2020, 9, 269-279.	2.8	64
96	Cytosine Methylation Profiles as a Molecular Marker in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2006, 66, 10911-10918.	0.9	63
97	Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. Human Molecular Genetics, 2006, 15, 2038-2044.	2.9	63
98	Fragile Histidine Triad Gene Inactivation in Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 396-401.	5.6	63
99	Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 2012, 30, 1129-1136.	1.6	63
100	Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, djv246.	6.3	63
101	COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1133-1141.	2.5	63
102	Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral Oncology, 2000, 36, 404-413.	1.5	62
103	Comparison of discriminatory power and accuracy of three lung cancer risk models. British Journal of Cancer, 2010, 103, 423-429.	6.4	62
104	CT screening for lung cancer: countdown to implementation. Lancet Oncology, The, 2013, 14, e591-e600.	10.7	62
105	METH-2 silencing and promoter hypermethylation in NSCLC. British Journal of Cancer, 2004, 91, 1149-1154.	6.4	60
106	LLPi: Liverpool Lung Project Risk Prediction Model for Lung Cancer Incidence. Cancer Prevention Research, 2015, 8, 570-575.	1.5	60
107	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nature Communications, 2018, 9, 3221.	12.8	60
108	Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for trans-allele repression. Human Molecular Genetics, 2006, 15, 1271-1277.	2.9	57

#	Article	IF	Citations
109	Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics, 2009, 9, 74-86.	2.2	56
110	Outcomes of oral squamous cell carcinoma arising from oral epithelial dysplasia: rationale for monitoring premalignant oral lesions in a multidisciplinary clinic. British Journal of Oral and Maxillofacial Surgery, 2013, 51, 594-599.	0.8	55
111	Expression of the cell-cell adhesion molecule E-cadherin in squamous cell carcinoma of the head and neck. Clinical Otolaryngology, 2007, 18, 196-201.	0.0	54
112	Neuroglobin and myoglobin in non-small cell lung cancer: Expression, regulation and prognosis. Lung Cancer, 2011, 74, 411-418.	2.0	54
113	The Detection of thec-mycandrasOncogenes in Nasopharyngeal Carcinoma by Immunohistochemistry. Acta Oto-Laryngologica, 1994, 114, 105-109.	0.9	53
114	LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Human Pathology, 1999, 30, 1508-1514.	2.0	52
115	Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. British Journal of Oral and Maxillofacial Surgery, 2007, 45, 617-622.	0.8	52
116	Incorporation of a Genetic Factor into an Epidemiologic Model for Prediction of Individual Risk of Lung Cancer: The Liverpool Lung Project. Cancer Prevention Research, 2010, 3, 664-669.	1.5	51
117	Lung cancer screening: the way forward. British Journal of Cancer, 2008, 99, 557-562.	6.4	50
118	TPL2 kinase is a suppressor of lung carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1470-9.	7.1	50
119	Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. Cancers, 2020, 12, 1672.	3.7	50
120	Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model. Cancer Research, 2021, 81, 1607-1615.	0.9	50
121	Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. EBioMedicine, 2015, 2, 1677-1685.	6.1	49
122	Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Human Immunology, 2010, 71, 976-981.	2.4	48
123	Close mapping of the focal non-epidermolytic palmoplantar keratoderma (PPK) locus associated with oesophageal cancer (TOC). Human Molecular Genetics, 1996, 5, 857-860.	2.9	47
124	Global DNA hypomethylation-induced Î”Np73 transcriptional activation in non-small cell lung cancer. Cancer Letters, 2011, 300, 79-86.	7.2	47
125	E-Cigarettes and Cancer Patients. Journal of Thoracic Oncology, 2014, 9, 438-441.	1.1	46
126	Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung Cancer. Scientific Reports, 2017, 7, 42190.	3.3	46

#	Article	IF	Citations
127	hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Research, 2000, 60, 4216-21.	0.9	46
128	Expression of oncogenes in human tumours with special reference to the head and neck region. Journal of Oral Pathology and Medicine, 1987, 16, 97-107.	2.7	45
129	The tylosis esophageal cancer (Toc) locus: more than just a familial cancer gene*. Ecological Management and Restoration, 1999, 12, 173-176.	0.4	45
130	Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. Oncogene, 1994, 9, 2077-82.	5.9	45
131	CpG island methylation phenotype (CIMP) in oral cancer: Associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncology, 2007, 43, 878-886.	1.5	44
132	Respirable Crystalline Silica Exposure, Smoking, and Lung Cancer Subtype Risks. A Pooled Analysis of Caseâ€“Control Studies. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 412-421.	5.6	44
133	Unique volatolomic signatures of TP53 and KRAS in lung cells. British Journal of Cancer, 2014, 111, 1213-1221.	6.4	43
134	Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nature Communications, 2018, 9, 3927.	12.8	43
135	Mortality Reduction with Low-Dose CT Screening for Lung Cancer. New England Journal of Medicine, 2020, 382, 572-573.	27.0	43
136	S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. British Journal of Cancer, 2004, 91, 1515-1524.	6.4	42
137	A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene. Cancer Research, 2009, 69, 5210-5217.	0.9	42
138	Characterization of a 500â€‰kb region on 17q25 and the exclusion of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) locus. Oncogene, 2002, 21, 6395-6402.	5.9	41
139	Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5ï¿½kb: sequencing does not identify the causative gene. Human Genetics, 2004, 114, 534-540.	3.8	41
140	Lung cancer and DNA repair genes: multilevel association analysis from the International Lung Cancer Consortium. Carcinogenesis, 2012, 33, 1059-1064.	2.8	41
141	TP53 mutations in malignant and premalignant Barrettâ€™s esophagus. Ecological Management and Restoration, 2003, 16, 83-89.	0.4	40
142	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	1.1	40
143	Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme. Lung Cancer, 2019, 134, 66-71.	2.0	40
144	Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs). Molecular Medicine, 2000, 6, 208-237.	4.4	38

#	Article	IF	Citations
145	Effect Modification of the Association of Cumulative Exposure and Cancer Risk by Intensity of Exposure and Time Since Exposure Cessation: A Flexible Method Applied to Cigarette Smoking and Lung Cancer in the SYNERGY Study. American Journal of Epidemiology, 2014, 179, 290-298.	3.4	38
146	The management of oral epithelial dysplasia: The Liverpool algorithm. Oral Oncology, 2015, 51, 883-887.	1.5	38
147	Aurora B expression modulates paclitaxel response in non-small cell lung cancer. British Journal of Cancer, 2017, 116, 592-599.	6.4	38
148	p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. Cancer Research, 1997, 57, 4070-4.	0.9	38
149	Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q. Oncogene, 1998, 17, 2101-2105.	5.9	37
150	The Role of Pyrosequencing in Head and Neck Cancer Epigenetics. JAMA Otolaryngology, 2008, 134, 251.	1.2	37
151	C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Research, 1992, 12, 613-9.	1.1	37
152	Cytoglobin has bimodal: tumour suppressor and oncogene functions in lung cancer cell lines. Human Molecular Genetics, 2013, 22, 3207-3217.	2.9	36
153	Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci. Carcinogenesis, 2016, 37, 96-105.	2.8	36
154	The role of DNA methylation as biomarkers in the clinical management of lung cancer. Expert Review of Respiratory Medicine, 2013, 7, 363-383.	2.5	35
155	Pleiotropic Associations of Risk Variants Identified for Other Cancers With Lung Cancer Risk: The PAGE and TRICL Consortia. Journal of the National Cancer Institute, 2014, 106, dju061.	6.3	35
156	Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine, 2018, 32, 93-101.	6.1	35
157	Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. Cancer Research, 1999, 59, 2690-5.	0.9	35
158	Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer. Oncogene, 1999, 18, 987-993.	5.9	34
159	Envoplakin, a Possible Candidate Gene for Focal NEPPK/Esophageal Cancer (TOC): The Integration of Genetic and Physical Maps of the TOC Region on 17q25. Genomics, 1999, 59, 234-242.	2.9	34
160	Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck. Oral Oncology, 2003, 39, 115-129.	1.5	34
161	CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax, 2011, 66, 736-737.	5.6	34
162	Lung cancer risk among bricklayers in a pooled analysis of caseâ€“control studies. International Journal of Cancer, 2015, 136, 360-371.	5.1	34

#	Article	IF	Citations
163	CT screening for lung cancer: Is the evidence strong enough?. Lung Cancer, 2016, 91, 29-35.	2.0	34
164	Diesel Engine Exhaust Exposure, Smoking, and Lung Cancer Subtype Risks. A Pooled Exposureâ€“Response Analysis of 14 Caseâ€“Control Studies. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 402-411.	5.6	34
165	Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung disease. Lung Cancer, 2000, 28, 37-42.	2.0	33
166	Transcriptomeâ€wide association study reveals candidate causal genes for lung cancer. International Journal of Cancer, 2020, 146, 1862-1878.	5.1	33
167	Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Research, 2001, 61, 1624-8.	0.9	33
168	Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. British Journal of Cancer, 2002, 87, 1308-1313.	6.4	32
169	Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. British Journal of Cancer, 2014, 110, 1834-1840.	6.4	32
170	Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers. International Journal of Epidemiology, 2019, 48, 751-766.	1.9	32
171	Lung cancer among coal miners, ore miners and quarrymen: smoking-adjusted risk estimates from the synergy pooled analysis of caseâ€“control studies. Scandinavian Journal of Work, Environment and Health, 2015, 41, 467-477.	3.4	32
172	Clinical relevance of oncogene expression in head and neck tumours. Anticancer Research, 1986, 6, 595-600.	1.1	32
173	Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer. British Journal of Cancer, 1996, 74, 1968-1974.	6.4	31
174	Trends and regional variation in the incidence of head and neck cancers in England: 2002 to 2011. International Journal of Oncology, 2015, 47, 204-210.	3.3	31
175	Management of proliferative verrucous leukoplakia: Justification for a conservative approach. Head and Neck, 2017, 39, 1997-2003.	2.0	31
176	Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review. BMC Cancer, 2019, 19, 1068.	2.6	31
177	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	12.8	31
178	Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene, 1995, 11, 581-5.	5.9	31
179	Genomic instability in squamous cell carcinoma of the head and neck. Anticancer Research, 1996, 16, 2421-31.	1.1	31
180	Sensitivity and limitations of high throughput fluorescent microsatellite analysis for the detection of allelic imbalance: application in lung tumors.. International Journal of Oncology, 2000, 16, 5-14.	3.3	30

#	Article	IF	Citations
181	Seizure 6-Like (SEZ6L) Gene and Risk for Lung Cancer. Cancer Research, 2007, 67, 8406-8411.	0.9	30
182	Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion. ESMO Open, 2019, 4, e000577.	4.5	30
183	Multiple cytogenetic aberrations in squamous cell carcinomas of the head and neck. European Journal of Cancer Part B, Oral Oncology, 1992, 28, 17-21.	0.9	29
184	Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis, 2018, 39, 336-346.	2.8	29
185	Analysis of the baseline performance of five UK lung cancer screening programmes. Lung Cancer, 2021, 161, 136-140.	2.0	29
186	Implementation planning for lung cancer screening in China. Precision Clinical Medicine, 2019, 2, 13-44.	3.3	28
187	Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. Thorax, 2019, 74, 761-767.	5.6	28
188	Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives. British Journal of Cancer, 2006, 95, 1288-1290.	6.4	27
189	A concordance index for matched case-control studies with applications in cancer risk. Statistics in Medicine, 2015, 34, 396-405.	1.6	27
190	The causal relevance of body mass index in different histological types of lung cancer: A Mendelian randomization study. Scientific Reports, 2016, 6, 31121.	3.3	27
191	Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. International Archives of Occupational and Environmental Health, 2018, 91, 937-950.	2.3	27
192	Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1Ll Region. Journal of Thoracic Oncology, 2019, 14, 1360-1369.	1.1	27
193	Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. Thorax, 2021, 76, 161-168.	5.6	27
194	Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Investigative Ophthalmology and Visual Science, 2001, 42, 2472-7.	3.3	27
195	Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. British Journal of Cancer, 1995, 71, 995-998.	6.4	26
196	Expression ofp16INK4A and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: Relationship with tumor growth parameters and ploidy status. , 2000, 89, 133-141.		26
197	AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. Oncology Letters, 2017, 13, 4463-4468.	1.8	26
198	Chromosome 18: a possible site for a tumour suppressor gene deletion in squamous cell carcinoma of the head and neck. Clinical Otolaryngology, 1995, 20, 266-271.	1.2	25

#	Article	IF	Citations
199	Association of allelic loss at theFHIT locus andp53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Journal of Pathology, 2001, 193, 55-65.	4.5	25
200	Measurement Methods and Algorithms for the Management of Solid Nodules. Journal of Thoracic Imaging, 2012, 27, 230-239.	1.5	25
201	A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. British Journal of Cancer, 2013, 109, 2404-2411.	6.4	25
202	Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. Oncotarget, 2019, 10, 1760-1774.	1.8	25
203	Lung cancer screening: identifying the high risk cohort. Journal of Thoracic Disease, 2015, 7, S156-62.	1.4	25
204	p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. International Journal of Cancer, 2002, 101, 248-252.	5.1	24
205	Glycine-Extended Gastrin Promotes the Growth of Lung Cancer. Cancer Research, 2004, 64, 196-201.	0.9	24
206	p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck. International Journal of Cancer, 1997, 71, 796-799.	5.1	23
207	A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer. Lung Cancer, 2002, 37, 143-146.	2.0	23
208	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. Journal of Thoracic Oncology, 2014, 9, 141-143.	1.1	23
209	Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility. Nature Communications, 2020, 11, 27.	12.8	23
210	A physical and microbiological evaluation of the re-use of non-sterile gloves. British Dental Journal, 1988, 165, 321-324.	0.6	23
211	Fractional allele loss indicates distinct genetic populations in the development of squamous cell carcinoma of the head and neck (SCCHN). Carcinogenesis, 1999, 20, 2219-2228.	2.8	22
212	Microsatellite Instability and p53 Mutations in Hepatocellular Carcinoma. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 1999, 2, 155-161.	1.6	22
213	Absence of mutations in the VHL gene but frequent loss of heterozygosity at 3p25â€“26 in non-small cell lung carcinomas. Lung Cancer, 2003, 39, 273-277.	2.0	22
214	A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. BMC Genomics, 2013, 14, S5.	2.8	22
215	Perceptions towards electronic cigarettes for smoking cessation among Stop Smoking Service users. British Journal of Health Psychology, 2016, 21, 421-433.	3.5	22
216	Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1483-1495.	1.1	22

#	Article	IF	Citations
217	The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. Lung Cancer, 2021, 152, 58-65.	2.0	22
218	Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 683-689.	2.8	21
219	The contribution of risk prediction models to early detection of lung cancer. Journal of Surgical Oncology, 2013, 108, 304-311.	1.7	21
220	Electronic cigarettes: a survey of perceived patient use and attitudes among members of the British thoracic oncology group. Respiratory Research, 2016, 17, 55.	3.6	21
221	The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial. European Radiology, 2018, 28, 226-234.	4.5	21
222	Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 935-942.	2.5	21
223	Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma. Frontiers of Medicine, 2021, 15, 275-291.	3.4	21
224	The Liverpool Statement 2005: Priorities for the European Union/United States Spiral Computed Tomography Collaborative Group. Journal of Thoracic Oncology, 2006, 1, 497-498.	1.1	21
225	Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene. Cancer Genetics and Cytogenetics, 2001, 126, 147-154.	1.0	20
226	Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model. International Journal of Oncology, 2016, 49, 361-370.	3.3	20
227	Rare deleterious germline variants and risk of lung cancer. Npj Precision Oncology, 2021, 5, 12.	5.4	19
228	Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. PLoS Genetics, 2021, 17, e1009254.	3.5	19
229	Molecular Biomarkers Workshop: a European Strategy for Developing Lung Cancer Molecular Diagnostics in High Risk Populations. Lung Cancer, 2001, 31, 339-345.	2.0	18
230	Generation of a non-small cell lung cancer transcriptome microarray. BMC Medical Genomics, 2008, 1, 20.	1.5	18
231	Lung Cancer Risk Models Come of Age: Fig. 1. Cancer Prevention Research, 2008, 1, 226-228.	1.5	18
232	Perspective: The screening imperative. Nature, 2014, 513, S7-S7.	27.8	18
233	Occupational prestige, social mobility and the association with lung cancer in men. BMC Cancer, 2016, 16, 395.	2.6	18
234	Presentation of lung cancer in primary care. Npj Primary Care Respiratory Medicine, 2019, 29, 21.	2.6	18

#	Article	IF	Citations
235	The Liverpool Lung Project research protocol. International Journal of Oncology, 2005, 27, 1633-45.	3.3	18
236	A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians. Journal of Thoracic Oncology, 2022, 17, 974-990.	1.1	18
237	A microcomputer program for analysis of nucleic acid hybridizatoin data. Nucleic Acids Research, 1982, 10, 1411-1421.	14.5	17
238	The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection. European Respiratory Journal, 2002, 20, 464-479.	6.7	17
239	Methylation discriminators in NSCLC identified by a microarray based approach. International Journal of Oncology, 2005, 27, 105-11.	3.3	17
240	Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: Results from a multi-centre caseâ€“control study in Europe. European Journal of Cancer, 2009, 45, 3047-3053.	2.8	17
241	Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73Î³ in lung cancer. FEBS Journal, 2010, 277, 3014-3027.	4.7	17
242	Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. Lung Cancer, 2012, 75, 156-160.	2.0	17
243	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. Human Molecular Genetics, 2015, 24, 7406-7420.	2.9	17
244	The Knights of the Round Table hypothesis of tumour suppressor gene function--noble sacrifice or sexual dalliance: genes, including p53, BRCA1/2 and RB have evolved by horizontal and vertical transmission of mating factor genes and are involved in gametogenesis, implantation, development and tumourigenesis.. International Journal of Oncology, 1998, 12, 5-35.	3.3	16
245	Three different subsite classification systems for carcinomas in the proximity of the GEJ, but is it all one disease?. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 24-30.	2.8	16
246	Molecular basis of familial cleft lip and palate. Oral Diseases, 1996, 2, 238-241.	3.0	16
247	A further study of the inheritance of racing performance in thoroughbred horses. Journal of Heredity, 1976, 67, 247-248.	2.4	15
248	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 2009, 34, 1477-1486.	6.7	15
249	Impact of comorbidity on lung cancer mortality - a report from the Liverpool Lung Project. Oncology Letters, 2015, 9, 1902-1906.	1.8	15
250	Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. Carcinogenesis, 2015, 36, 1314-1326.	2.8	15
251	Lung Cancer Among Firefighters. Journal of Occupational and Environmental Medicine, 2016, 58, 1137-1143.	1.7	15
252	Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. European Journal of Radiology, 2019, 120, 108646.	2.6	15

#	Article	IF	Citations
253	Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial. British Journal of Radiology, 2016, 89, 20160301.	2.2	14
254	Lung cancer CT screening: is annual screening necessary?. Lancet Oncology, The, 2016, 17, 543-544.	10.7	14
255	Von Hippel-Lindau Tumour Suppressor Gene Is Not Involved in Sporadic Human Breast Cancer. Tumor Biology, 2001, 22, 131-136.	1.8	13
256	Electronic cigarette use and risk perception in a Stop Smoking Service in England. Addiction Research and Theory, 2015, 23, 336-342.	1.9	13
257	Implementation planning for lung cancer screening: five major challenges. Lancet Respiratory Medicine,the, 2016, 4, 685-687.	10.7	13
258	The International Association for the Study of Lung Cancer Early Lung Imaging Confederation. JCO Clinical Cancer Informatics, 2020, 4, 89-99.	2.1	13
259	Abstract 1531: Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets. , 2014, , .		13
260	Selection of eligible participants for screening for lung cancer using primary care data. Thorax, 2022, 77, 882-890.	5.6	13
261	Low levels of ras p21 oncogene expression correlates with clinical outcome in head and neck squamous cell carcinoma. European Journal of Surgical Oncology, 1992, 18, 168-76.	1.0	13
262	Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung. Anticancer Research, 1990, 10, 1105-14.	1.1	13
263	p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. British Journal of Cancer, 1997, 75, 1119-1124.	6.4	12
264	Reactors: A data-oriented synchronous/asynchronous programming model for distributed applications. Theoretical Computer Science, 2009, 410, 168-201.	0.9	12
265	Lung cancer risk among bakers, pastry cooks and confectionary makers: the SYNERGY study. Occupational and Environmental Medicine, 2013, 70, 810-814.	2.8	12
266	A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer. Annals of Oncology, 2014, 25, 781-791.	1.2	12
267	Expression of the cellâ€“cell adhesion molecule E-cadherin in tongue carcinoma cell lines. Journal of Laryngology and Otology, 1994, 108, 957-961.	0.8	11
268	An immunohistochemical analysis of p53 protein expression in pre-malignant and malignant tissues of the oral cavity. Clinical Otolaryngology, 1997, 22, 23-29.	0.0	11
269	Risk assessment in relation to the detection of small pulmonary nodules. Translational Lung Cancer Research, 2017, 6, 35-41.	2.8	11
270	Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium. PLoS ONE, 2017, 12, e0185660.	2.5	11

#	Article	IF	Citations
271	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1228-1237.	2.5	11
272	Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors. Cancer Research, 2022, 82, 199-209.	0.9	11
273	Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report. Journal of Thoracic Oncology, 2021, , .	1.1	11
274	Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: A European strategy for developing lung cancer molecular diagnostics in high risk populations. International Journal of Oncology, 2002, 21, 369-73.	3.3	10
275	Major conceptual change required to improve lung cancer: see a respiratory physician. European Respiratory Journal, 2003, 21, 565-566.	6.7	10
276	Defining high-risk individuals in a population-based molecular-epidemiological study of lung cancer. International Journal of Oncology, 2006, 28, 1295.	3.3	10
277	Improving care for patients with lung cancer in the UK. Thorax, 2013, 68, 1181-1185.	5.6	10
278	Optimum low dose CT screening interval for lung cancer: the answer from NELSON?. Thorax, 2017, 72, 6-7.	5.6	10
279	Genetic Determinants of Lung Cancer Prognosis in Never Smokers: A Pooled Analysis in the International Lung Cancer Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1983-1992.	2.5	10
280	The potential for using risk models in future lung cancer screening trials. F1000 Medicine Reports, 2010, 2, .	2.9	10
281	Occupational Exposure to Polycyclic Aromatic Hydrocarbons and Lung Cancer Risk: Results from a Pooled Analysis of Caseâ€“Control Studies (SYNERGY). Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1433-1441.	2.5	10
282	TheVon Hippel-Lindau (VHL) tumor-suppressor gene is not mutated in sporadic human colon adenocarcinomas. International Journal of Cancer, 2000, 88, 503-505.	5.1	9
283	Allelic imbalance at the 5q14 locus is associated with decreased apoptotic rate in non-small cell lung carcinomas (NSCLCs). Possible synergistic effect with p53 gene alterations on apoptosis. Lung Cancer, 2000, 28, 211-224.	2.0	9
284	An investigation of the tylosis with oesophageal cancer (TOC) locus in Iranian patients with oesophageal squamous cell carcinoma. International Journal of Oncology, 2004, 25, 389-95.	3.3	9
285	Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 1467-1472.	2.4	9
286	Lung Cancer Risk Among Cooks When Accounting for Tobacco Smoking. Journal of Occupational and Environmental Medicine, 2015, 57, 202-209.	1.7	9
287	The role of screening expectations in modifying shortâ€“term psychological responses to low-dose computed tomography lung cancer screening among high-risk individuals. Patient Education and Counseling, 2017, 100, 1572-1579.	2.2	9
288	Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer. Oncology Reports, 2017, 38, 1915-1922.	2.6	9

#	Article	IF	Citations
289	A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival. Npj Precision Oncology, 2021, 5, 39.	5.4	9
290	Immunohistochemical Analysis of the Expression of the c-myc Oncoprotein in Human Stomach Cancers. Digestion, 1991, 50, 127-134.	2.3	8
291	Prognostic significance of oncogenes and tumor suppressor genes in human malignancy. Stem Cells, 1993, 11, 194-198.	3.2	8
292	The treatment of early squamous cell carcinoma of the piriform fossa. Clinical Otolaryngology, 1994, 19, 485-490.	1.2	8
293	Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. International Journal of Oncology, 2010, 37, 455-61.	3.3	8
294	Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma. Cancer, 2000, 89, 1933-1945.	4.1	8
295	Exposure to Cigarette Smoke and Expression of the Protein Encoded by the p53 Gene in Bronchial Carcinoma. Annals of the New York Academy of Sciences, 1993, 686, 243-247.	3.8	7
296	c-mos immunoreactivity is an indicator of good prognosis in lung cancer. Histopathology, 2000, 37, 45-54.	2.9	7
297	Sequencing of Difficult Templates Containing Poly(A/T) Tracts: Closure of Sequence Gaps. BioTechniques, 2002, 33, 276-280.	1.8	7
298	A global approach to cancer-screening trials. Lancet Oncology, The, 2008, 9, 908-909.	10.7	7
299	MyLungRisk: a user-friendly, web-based calculator for risk assessment of lung cancer based on the validated Liverpool Lung Project risk prediction model. International Journal of Health Promotion and Education, 2014, 52, 144-152.	0.9	7
300	Genomeâ€wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk. International Journal of Cancer, 2020, 146, 2855-2864.	5.1	7
301	Integration of multiomic annotation data to prioritize and characterize inflammation and immuneâ€related risk variants in squamous cell lung cancer. Genetic Epidemiology, 2021, 45, 99-114.	1.3	7
302	Genomic Instability in Head and Neck Cancer. Current Topics in Pathology Ergebnisse Der Pathologie, 1996, 90, 201-222.	0.2	7
303	Telomerase activity in non-small cell lung carcinomas correlates with smoking status.. International Journal of Oncology, 1999, 15, 961-5.	3.3	6
304	Physical and transcript map of the minimally deleted region III on 17p implicated in the early development of Barrett's oesophageal adenocarcinoma. Oncogene, 2003, 22, 4134-4142.	5.9	6
305	Progressive lung cancer determined by expression profiling and transcriptional regulation. International Journal of Oncology, 2012, 41, 242-52.	3.3	6
306	Factors associated with dropout in a lung cancer high-risk cohort - the Liverpool lung project. International Journal of Oncology, 2014, 44, 2146-2152.	3.3	6

#	Article	IF	Citations
307	Lung cancer trend in England for the period of 2002 to 2011 and projections of future burden until 2020. International Journal of Oncology, 2015, 47, 739-746.	3.3	6
308	Association between smoking and health outcomes in an economically deprived population: the Liverpool Lung Project. Journal of Epidemiology and Community Health, 2017, 71, 806-810.	3.7	6
309	Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium. Clinical Cancer Research, 2017, 23, 7550-7557.	7.0	6
310	Utilizing Lung Cancer Risk Prediction Models to Promote Smoking Cessation: Two Randomized Controlled Trials. American Journal of Health Promotion, 2018, 32, 1196-1205.	1.7	6
311	Lung cancer CT screening: are we ready to consider screening biennially in a subgroup of low-risk individuals?. Thorax, 2018, 73, 1006-1007.	5.6	6
312	Association Analysis of Driver Geneâ€“Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1423-1429.	2.5	6
313	Histological and molecular mapping of adenocarcinoma of the oesophagus and gastroesophageal junction: loss of heterozygosity occurs in histologically normal epithelium in the oesophagus and stomach.. Oncology Reports, 2000, 7, 521-8.	2.6	6
314	Non-squamous malignancy in lymph nodes: the occult primary. Clinical Otolaryngology, 1993, 18, 311-316.	1.2	5
315	Oral tylosis: a re-appraisal. Oral Oncology, 1997, 33, 55-57.	1.5	5
316	A comparative guide to gene prediction tools for the bioinformatics amateur. International Journal of Oncology, 2002, 20, 697-705.	3.3	5
317	Detection of DNA Methylation Changes in Body Fluids. Advances in Genetics, 2010, 71, 177-207.	1.8	5
318	P1.04: Defining the Genetic Architecture of Lung Cancer Etiology. Journal of Thoracic Oncology, 2016, 11, S182.	1.1	5
319	EU Policy on Lung Cancer CT Screening 2017. Biomedicine Hub, 2017, 2, 1-8.	1.2	5
320	EUPSâ€”argues that lung cancer screening should be implemented in 18 months. British Journal of Radiology, 2018, 91, 20180243.	2.2	5
321	Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis, 2019, 40, 432-440.	2.8	5
322	The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. Journal of Thoracic Oncology, 2006, 1, 497-8.	1.1	5
323	A Phase II study of cisplatinum versus cisplatinum + nifedipine in end-stage carcinoma of the head and neck. Clinical Otolaryngology, 1992, 17, 501-504.	1.2	4
324	The treatment of node negative squamous cell carcinoma of the postcricoid region. Journal of Laryngology and Otology, 1995, 109, 114-119.	0.8	4

#	Article	IF	Citations
325	Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer. Journal of Thoracic Disease, 2016, 8, 2357-2359.	1.4	4
326	Is Bootstrapping Sufficient for Validating a Risk Model for Selection of Participants for a Lung Cancer Screening Program?. Journal of Clinical Oncology, 2017, 35, 818-819.	1.6	4
327	Prognostic Implications of ras Oncogene Expression in Head and Neck Squamous Cell Carcinoma. , 1991, , 213-226.		4
328	The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. Journal of the Royal Society of Medicine, 1995, 88, 35P-39P.	2.0	4
329	Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk. Human Molecular Genetics, 2022, 31, 2831-2843.	2.9	4
330	Technical forum: Using logical data models for understanding and transforming legacy business applications. IBM Systems Journal, 2006, 45, 647-655.	3.0	3
331	Environmental and Genetic Risk Factors of Lung Cancer. , 2007, , 67-100.		3
332	Education and Lung Cancer Among Never Smokers. Epidemiology, 2014, 25, 934-935.	2.7	3
333	Low-dose CT for lung cancer screening â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e135-e136.	10.7	3
334	Lung cancer: a potential role for dentists. British Dental Journal, 2020, 228, 413-414.	0.6	3
335	Time, steam, temperature (TST) control indicators to measure essential sterilisation criteria for autoclaves in general dental practice and the community dental service. British Dental Journal, 1988, 164, 183-186.	0.6	3
336	Development and validation of a multivariable risk prediction model for head and neck cancer using the UK Biobank. International Journal of Oncology, 2020, 57, 1192-1202.	3.3	3
337	Attitudes towards the integration of smoking cessation into lung cancer screening in the United Kingdom: A qualitative study of individuals eligible to attend. Health Expectations, 2022, 25, 1703-1716.	2.6	3
338	Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancer. International Journal of Oncology, 1992, 34, 465.	3.3	2
339	Tobacco money: up in smoke?. Lancet, The, 2002, 360, 1979-1980.	13.7	2
340	Development and performance evaluation of a CE-IVD for measuring SHOX2 DNA methylation in bronchial aspirates for the diagnosis of lung cancer. Lung Cancer, 2012, 77, S22.	2.0	2
341	Predictive Accuracy of the Liverpool Lung Project Risk Model. Annals of Internal Medicine, 2013, 158, 568.	3.9	2
342	Lung cancer screening with low dose computed tomography. BMJ, The, 2014, 348, g1970-g1970.	6.0	2

#	Article	IF	Citations
343	Abstract 3631: United Kingdom lung cancer screening trial (UKLS): First 88897 approaches.. Cancer Research, 2013, 73, 3631-3631.	0.9	2
344	Abstract 4220: Liverpool healthy lung project: a primary care initiative to identify hard to reach individuals with a high risk of developing lung cancer. , 2017, , .		2
345	Molecular Pathological Mechanisms in NSCLC and the Assessment of Individuals with a High Risk of Developing Lung Cancer. , 1998, , 247-261.		2
346	Iam hiQâ€”a novel pair of accuracy indices for imputed genotypes. BMC Bioinformatics, 2022, 23, 50.	2.6	2
347	Peptide amidating activity in human bronchoalveolar lavage fluid: relationship to lung cancer, inflammation and infection.. International Journal of Oncology, 2000, 16, 327-32.	3.3	1
348	M09-03: Biomarkers and risk models for stratification of high risk individuals. Journal of Thoracic Oncology, 2007, 2, S176.	1.1	1
349	Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial. Translational Lung Cancer Research, 2018, 7, S114-S116.	2.8	1
350	Application of two job indices for general occupational demands in a pooled analysis of caseâ€“control studies on lung cancer. Scandinavian Journal of Work, Environment and Health, 2021, 47, 475-481.	3.4	1
351	The Von HippelLindau VHL tumorâ€suppressor gene is not mutated in sporadic human colon adenocarcinomas. International Journal of Cancer, 2000, 88, 503-505.	5.1	1
352	Abstract 5358: Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma. , 2018, , .		1
353	Risk prediction models in lung cancer: The methodology for identifying high risk individuals for future lung cancer computed tomography (CT) screening programs. AACR Education Book, 2015, 2015, 125-132.	0.0	1
354	Abstract 3571: UKLS - United Kingdom Lung Cancer Screening Trial. Cancer Research, 2012, 72, 3571-3571.	0.9	1
355	Accounting for EGFR Mutations in Epidemiologic Analyses of Nonâ€“Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 679-687.	2.5	1
356	Geneâ€“gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer. European Journal of Medical Research, 2022, 27, 14.	2.2	1
357	A new rare allele at the CGG repeat polymorphism in the first intron of human c-H-ras gene. In Vivo, 2001, 15, 105-8.	1.3	1
358	The Response to Hormones and Anti-Hormones of Human Breast Tumour Cells Grown in Continuous Culture. Biochemical Society Transactions, 1978, 6, 1318-1319.	3.4	0
359	EFFECTS OF OESTROGENS ON THE COMPLEXITY OF POLY (A) RNA FROM RAT UTERUS. Biochemical Society Transactions, 1981, 9, 153P-153P.	3.4	0
360	Fluorescent Microsatellite Analysis in Bronchial Lavage as a Potential Diagnostic Tool for Lung Cancer. , 2003, 75, 251-262.		0

#	Article	IF	Citations
361	E-26. Molecular markers in early detection. Lung Cancer, 2003, 41, S33-S34.	2.0	0
362	Early detection of lung cancer with low-dose computed tomography: an update on recently presented data. Lung Cancer Management, 2012, 1, 189-194.	1.5	0
363	Selected Papers from the Eleventh International Conference on Coordination Models and Languages. Science of Computer Programming, 2012, 77, 661-662.	1.9	0
364	Authors' response. Thorax, 2013, 68, 105.2-105.	5.6	0
365	Conference Scene: 11th Annual British Thoracic Oncology Group Conference 2013. Lung Cancer Management, 2013, 2, 103-105.	1.5	0
366	Response to Oral epithelial dysplasia in oral submucous fibrosis: A challenge. Oral Oncology, 2016, 54, e20.	1.5	0
367	A reply to â€œLung cancer outcomes: Are BMI and race clinically relevant?â€• Lung Cancer, 2021, 154, 225-226.	2.0	0
368	Abstract 4826: International Lung Cancer Consortium: Pooled analysis of previous lung diseases and lung cancer risk. , 2010, , .		0
369	Abstract 163: DTMETH: A novel method for increased length quantitative CpG methylation analysis. , 2010, , .		0
370	Abstract 2251: High VEGFA pathway expression predicts good prognosis in stage I squamous cell carcinoma of the lung. , 2011, , .		0
371	Abstract 1898: The Liverpool Lung Project risk model: An independent validation and clinical utility in primary care. , 2011, , .		0
372	Abstract 4133: MicroRNAs for early detection of lung cancer. , 2012, , .		0
373	Lung Cancer Screening. , 2015, , 1-11.		0
374	Computed Tomography Characterisation of Lung Nodules and Management of Incidentally Detected Nodules. Medical Radiology, 2016, , 183-193.	0.1	0
375	Abstract 2569: A genome wide association study of lung cancer identifies 11 novel susceptibility loci. , 2016, , .		0
376	Abstract 817: Mendelian randomization and mediation analysis of 5p15.33, telomere length and lung cancer risk. , 2016, , .		0
377	Abstract 3458: UK lung cancer screening trial (UKLS) cost effectiveness: similarities with the NLST high-risk quintiles. , 2016, , .		0
378	Abstract IA17: Risk prediction modeling in lung cancer: How can we improve?. , 2017, , .		0

#	Article	IF	Citations
379	Abstract 2248: CommonTDP1polymorphisms in relation to survival among small cell lung cancer patients in a multicenter study from the International Lung Cancer Consortium. , 2017, , .		0
380	Abstract 2292: Lung function and lung cancer risk: a Mendelian randomization study of UK Biobank cohort and the International Lung Cancer Consortium. , 2017, , .		0
381	Understanding the lung cancer mortality reductions produced by low-dose CT screeningâ€"Authorsâ€™ reply. Lancet Regional Health - Europe, The, 2022, 12, 100259.	5.6	0
382	Abstract LB-053: Familial studies identify variants in the E2A transcription factor as putative risk factors for lung cancer. , 2019, , .		0